Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SumMET first-in-human study of [225Ac]Ac-FL-261 in c-MET overexpressing solid tumors
CTR20263878Phase 2Active
- Sponsor
- Full-Life Technologies
- Start
- Oct 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of [225Ac]Ac-FL-261 in Nonhematologic neoplasms, sponsored by Full-Life Technologies. Started Oct 2026; status: active.
02
Drugs
[225Ac]Ac-FL-261
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20263878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263878.